Alzheimer's disease(AD) is a refractory neurodegenerative disease clinically characterized by memory loss and cognitive and behavioral dysfunction. The main pathological features of AD include neuronal loss, β-amyloid protein(Aβ) deposition and neurofibrillary tangles (NFTs), and numerous studies have shown that these may be triggered by neuronal death and neuroinflammation Receptor-interacting serine/threonine-protein kinase 1(RIPK1) is a serine/threonine kinase present at the intersection of cell death and inflammatory signaling pathways.Studies in recent years have revealed a potential role of RIPK1 on the progress of AD. In this paper, we summarized the links between RIPK1-mediated necroptosis and AD treatment from the aspects of neuronal death, inflammasome activation, blood-brain barrier breakdown and mitochondrial dysfunction, and the targeted treatment of RIPK1, the new findings of RIPK1 inhibitors and ongoing clinical trials, aiming to provide new ideas for the treatment of AD.

Objective:This paper aims to explore the management of human genetic resources in medical institutions, according to reflections of the management mode of a particular hospital, providing possible reference for other medical institutions.Methods:The management system of human genetic resources was constructed refer to the McKinsey 7S model. Approved projects information includes the types of projects, characteristics of human genetic resources involved and the characteristics of principal investigator are analyzed.Results:A total number of 82 projects were approved Since the implementation of newly updated Regulation of the People′s Republic of China on the Administration of Human Genetic Resources (hereinafter referred to as the regulations), and majority of which are drug clinical trials. The human genetic resources materials and data involved are mainly blood, urine, serum, plasma, clinical data, imaging data, etc. Most of the principal investigators with senior professional title are from key disciplines.Conclusions:McKinsey 7S model provides a new reference path for medical institutions to carry out human genetic resources management.